Table 1: Summary of the various clinical & dosimetric pertinent facts about each case used in the study. The tumor motion as measured after binning into 10 phases is also shown. The patient was positioned using an abdominal compression device.
| Patient | Sex | Age (y) | Lung Lobe | ITV(cm3) | PTV(cm3) | Lateral motion (mm) | Superior/Inferior motion (mm) | Anterior/Posterior motion (mm) |
| 1 | M | 77 | RUL | 4.42 | 15.96 | 2.0 | 1.8 | 3.9 |
| 2 | M | 75 | RUL | 4.77 | 23.73 | 3.8 | 2.1 | 4.4 |
| 3 | F | 70 | RUL | 4.59 | 24.39 | 2.3 | 1.4 | 4.6 |
| 4 | F | 77 | RUL | 7.38 | 32.99 | 1.9 | 3.2 | 1.4 |
| 5 | F | 80 | RUL | 3.90 | 24.50 | 1.3 | 1.7 | 1.3 |
| 6 | F | 83 | RML | 7.48 | 31.26 | 0.9 | 4.0 | 2.2 |
| 7 | F | 73 | RML | 3.15 | 19.11 | 2.5 | 1.7 | 1.3 |
| 8 | F | 67 | RML | 6.47 | 28.87 | 2.2 | 4.8 | 3.4 |
| 9 | F | 72 | RML | 4.42 | 15.96 | 2.3 | 8.7 | 3.7 |
| 10 | F | 76 | RML | 8.91 | 37.71 | 1.4 | 1.8 | 1.4 |
| 11 | M | 74 | RLL | 8.54 | 35.34 | 1.2 | 4.6 | 0.7 |
| 12 | 12 | 68 | RLL | 7.03 | 29.35 | 1.4 | 8.3 | 2.2 |
| 13 | F | 80 | RLL | 3.85 | 19.84 | 1.5 | 8.1 | 5.0 |
| 14 | M | 68 | RLL | 3.85 | 20.28 | 1.1 | 6.4 | 2.3 |
| 15 | M | 82 | RLL | 5.57 | 25.52 | 2.3 | 9.2 | 1.9 |
| 16 | F | 85 | LUL | 4.46 | 18.03 | 0.9 | 0.7 | 1.1 |
| 17 | M | 80 | LUL | 5.58 | 20.40 | 2.3 | 2.8 | 2.4 |
| 18 | M | 80 | LUL | 7.60 | 35.73 | 1.1 | 1.7 | 1.3 |
| 19 | M | 82 | LUL | 6.15 | 29.24 | 1.1 | 2.4 | 1.1 |
| 20 | M | 81 | LUL | 6.15 | 22.73 | 1.5 | 2.7 | 1.6 |
| 21 | F | 76 | LLL | 5.01 | 18.26 | 1.1 | 1.1 | 1.3 |
| 22 | F | 84 | LLL | 4.54 | 22.92 | 1.8 | 3.9 | 2.6 |
| 23 | M | 72 | LLL | 11.43 | 33.37 | 3.5 | 5.1 | 3.6 |
| 24 | F | 82 | LLL | 14.9 | 49.72 | 2.7 | 5.6 | 3.1 |
| 25 | M | 78 | LLL | 8.12 | 35.71 | 1.8 | 2.3 | 2.6 |